Bendamustine +Rituximab (BR) for CLL
Bendamustine +Rituximab (BR) for CLL INDICATIONS 1. Treatment naïve TP53 wild-type CLL (NICE TA216) 2. Patients with relapsed B-cell chronic lymphocytic leukaemia (B-CLL) who are not eligible for treatment with BTK or BCL2 inhibitors. (not routinely commissioned by NHSE) NB.
Tags:
Chronic, Bendamustine, Rituximab, Leukaemias, Lymphocytic, Chronic lymphocytic leukaemia
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Documents from same domain
Guidelines for the Management of Hypomagnesaemia …
nssg.oxford-haematology.org.ukDepartment of Clinical Haematology H.95 Page 2 of 5 November 2015 V.1.0. Guidelines for the management of hypomagnesaemia in Adult Clinical Haematology
Management, Hypomagnesaemia, For the management of hypomagnesaemia
ISATUXIMAB WITH POMALIDOMIDE AND …
nssg.oxford-haematology.org.ukvolume Initial rate Absence of infusion reaction Rate increment Maximum rate First infusion 250 mL 25 mL/ hour For 60 minutes 25 mL/hour every 30 minutes 150 mL/ hour Second infusion 250 mL 50 mL/ hour For 30 minutes 50 mL/ hour for 30 minutes then increase by 100 mL/ hr every 30 minutes 200 mL/ hour Subsequent infusions
With, Volume, Increment, Pomalidomide, Isatuximab with pomalidomide and, Isatuximab
CYCLOPHOSPHAMIDE / BORTEZOMIB/ …
nssg.oxford-haematology.org.ukMyeloma group This is a controlled document and therefore must not be changed of MM.11 CyBorDex- Amyloidosis Authorised by …
Cyclophosphamide priming prior to PBSC harvest
nssg.oxford-haematology.org.ukDepartment of Clinical Haematology Oxford BMT Programme B.2.20b Page 1 of 3 May 2017 V.5.4 Cyclo prime for Myeloma PSBC Harvest Authorised by: Dr Karthik Ramasamy
ATTENUATED CYCLOPHOSPHAMIDE, THALIDOMIDE & …
nssg.oxford-haematology.org.ukMyeloma group This is a controlled document and therefore must not be changed MM.9 CTD - attenuated Authorised by Myeloma lead Dr. Karthik Ramasamy July 2017
Oxford Myeloma Group
nssg.oxford-haematology.org.ukMM.50 VTDPACE/DTPACE Authorised by Myeloma lead Dr. Karthik Ramasamy June 2022 V. 2.0 of 10 Days Drug Dose Route Comments 1 to 4 Dexamethasone 40 mg daily Oral Continuous daily/ If PBSC harvest planned only for days 1 to 4 Thalidomide (See note below) Start 50 mg and increase up to 100 mg as tolerated Oral Nocte 1 to 4
MATRix (High dose METHOTREXATE, high dose CYTARABINE ...
nssg.oxford-haematology.org.uk- Reduce thiotepa dose to 75% - Reduce methotrexate to 2g/m2 Haematological toxicity In case if inadequate bone marrow recovery (i.e. neutrophils < 1.5x109/L and platelets < 90x109/L on the intended day of re-treatment, delay cycle until counts satisfactory. Doses of the chemotherapy
ATRA + ARSENIC TRIOXIDE
nssg.oxford-haematology.org.ukArsenic Trioxide infusion duration may be extended up to 4 hours if vasomotor reactions, e.g. flushing, tachycardia and dizziness, are observed. If patients suffer severe symptoms or hypotension then the infusion should be stopped until recovery and then recommenced at a
High dose METHOTREXATE (high grade NHL CNS …
nssg.oxford-haematology.org.ukadults receiving high-dose methotrexate chemotherapy (doses >1g/m2) - Who develop significant deterioration in renal function (>1.5x ULN and rising, or the presence of oliguria) OR - Have toxic plasma methotrexate level AND - Have been treated with all standard rescue and supportive measures AND
High, Grade, Dose, Chemotherapy, Methotrexate, High dose methotrexate, High grade nhl cns
ESHAP and R-ESHAP
nssg.oxford-haematology.org.uk2. Record stage of disease - contrast enhanced CT scan (neck, chest, abdomen and pelvis), ... In order to eliminate the risk of transmitting infective ... After 1-2 cycles with CT or PET-CT. Lymphoma group This is a controlled document and therefore must …
Related documents
Venetoclax and Obinutuzumab
nssg.oxford-haematology.org.ukFirst line treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) or Small Lymphocytic Lymphoma (SLL): 1. In the presence of 17p deletion or TP53 mutation (NICE TA663- BLUETEQ required). OR 2. In the absence of 17p deletion or TP53 mutation in adult patients for whom Fludarabine, Cyclophosphamide and Rituximab ...
First, Line, Chronic, Rituximab, Leukaemias, Lymphocytic, First line, Chronic lymphocytic leukaemia
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.euIMBRUVICA as a single agent or in combination with rituximab or obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section5.1). IMBRUVICA as a single agent or in combination with bendamustine and rituximab (BR)is indicated
Chronic, Bendamustine, Rituximab, Leukaemias, Lymphocytic, Chronic lymphocytic leukaemia